Abstract

Early diagnosis of acute mesenteric ischemia (AMI) remains a clinical challenge, and no biomarker has been consistently validated. We aimed to assess the accuracy of three promising circulating biomarkers for diagnosing AMI—citrulline, intestinal fatty acid-binding protein (I-FABP), and d-lactate. A cross-sectional diagnostic study enrolled AMI patients admitted to the intestinal stroke center and controls with acute abdominal pain of another origin. We included 129 patients—50 AMI and 79 controls. Plasma citrulline concentrations were significantly lower in AMI patients compared to the controls [15.3 μmol/L (12.0–26.0) vs. 23.3 μmol/L (18.3–29.8), p = 0.001]. However, the area under the receiver operating curves (AUROC) for the diagnosis of AMI by Citrulline was low: 0.68 (95% confidence interval = 0.58–0.78). No statistical difference was found in plasma I-FABP and plasma d-lactate concentrations between the AMI and control groups, with an AUROC of 0.44, and 0.40, respectively. In this large cross-sectional study, citrulline, I-FABP, and d-lactate failed to differentiate patients with AMI from patients with acute abdominal pain of another origin. Further research should focus on the discovery of new biomarkers.

Highlights

  • Management of acute mesenteric ischemia (AMI) can avoid fatal outcomes and prevent related short bowel ­syndrome[1,2,3,4]

  • Following the results of a pilot study showing an improvement in survival and lower resection r­ates[1], we created an intestinal stroke center (ISC) that provides 24/7 standardized multimodal and multidisciplinary care to AMI patients referred from the Paris r­egion[19]

  • For each of the continuous variables, we report the median and the interquartile range (IQR)

Read more

Summary

Introduction

Management of acute mesenteric ischemia (AMI) can avoid fatal outcomes and prevent related short bowel ­syndrome[1,2,3,4]. To this end, there is a dire need for tools to establish an immediate diagnosis. 48 were not included 17 vascular lesion with ssssno intestinal injury 14 chronic mesenteric ischemia 8 colon ischemia 6 no written consent 3 volvulus These factors, along with the heterogeneity of the disease, explain why identifying clinically reliable biological early markers of AMI has been unsuccessful so f­ar[2,4,9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call